{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:37:26Z","timestamp":1793173046430,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Dev Behav Pediatr"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>Reports on the pharmacologic treatment of anxiety, including generalized anxiety disorder (GAD), in individuals with Down syndrome (DS) are lacking.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We present the case histories of 1 adolescent and 2 young adults with DS and the treatment course of comorbid GAD with buspirone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Treatment with buspirone was safe and well-tolerated and resulted in sustained improvement in symptoms of anxiety for a minimum of 2 years in all 3 cases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Buspirone's generally benign adverse effect profile makes it well suited for treating anxiety in individuals with DS in light of their common medical comorbidities.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dbp.0000000000000970","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T11:26:00Z","timestamp":1620645960000},"page":"38-43","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Buspirone for the Treatment of Generalized Anxiety Disorder in Down Syndrome: 3 Cases"],"prefix":"10.1097","volume":"43","author":[{"given":"Yamini J.","family":"Howe","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA;"},{"name":"Lurie Center for Autism, Lexington, MA;"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn P.","family":"Thom","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA;"},{"name":"Lurie Center for Autism, Lexington, MA;"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Notson","sequence":"additional","affiliation":[{"name":"Oak Creek Franklin Joint School District, Oak Creek, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"McDougle","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA;"},{"name":"Lurie Center for Autism, Lexington, MA;"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA;"},{"name":"Lurie Center for Autism, Lexington, MA;"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"key":"R1-20250530","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-019-0143-7","article-title":"Down syndrome","volume":"6","author":"Antonarakis","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20250530","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jpeds.2013.06.013","article-title":"Current estimate of Down syndrome population prevalence in the United States","volume":"163","author":"Presson","year":"2013","journal-title":"J Pediatr"},{"key":"R4-20250530","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1192\/bjp.149.2.156","article-title":"Behavior problems in retarded children with special reference to Down's syndrome","volume":"149","author":"Gath","year":"1986","journal-title":"Br J Psychiatry"},{"key":"R5-20250530","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2788.2001.00335.x","article-title":"Psychopathology and young people with Down's syndrome: childhood predictors and adult outcome of disorder","volume":"45","author":"McCarthy","year":"2001","journal-title":"J Intellect Disabil Res"},{"key":"R6-20250530","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/dmcn.12868","article-title":"Morbidity and medication in a large population of individuals with Down syndrome compared to the general population","volume":"58","author":"Alexander","year":"2016","journal-title":"Dev Med Child Neurol"},{"key":"R7-20250530","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1080\/14656566.2018.1529167","article-title":"Pharmacotherapy of Down syndrome","volume":"19","author":"Palumbo","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"R9-20250530","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/00004583-199905000-00016","article-title":"Anxiolytics, adrenergic agents, and naltrexone","volume":"38","author":"Riddle","year":"1999","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R10-20250530","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1089\/cap.2018.0021","article-title":"A retrospective chart review of buspirone for the treatment of anxiety in psychiatrically referred youth with high-functioning autism spectrum disorder","volume":"29","author":"Ceranoglu","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R11-20250530","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4088\/JCP.v59n0203","article-title":"Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study","volume":"59","author":"Buitelaar","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R12-20250530","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jpeds.2015.11.033","article-title":"Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: a randomized trial","volume":"170","author":"Chugani","year":"2016","journal-title":"J Pediatr"},{"key":"R13-20250530","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s10803-019-04301-9","article-title":"Buspirone for the treatment of generalized anxiety disorder in Williams syndrome: a case series","volume":"50","author":"Thom","year":"2020","journal-title":"J Autism Dev Disord"},{"key":"R14-20250530","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/YPG.0000000000000218","article-title":"Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome: a case series","volume":"29","author":"Balaj","year":"2019","journal-title":"Psychiatr Genet"},{"key":"R15-20250530","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/00004583-200209000-00006","article-title":"The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties","volume":"41","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R16-20250530","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10566-010-9125-3","article-title":"The utility of clinicians ratings of anxiety using the Pediatric Anxiety Rating Scale (PARS)","volume":"40","author":"Ginsburg","year":"2011","journal-title":"Child Youth Care Forum"},{"key":"R19-20250530","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/ajmg.a.61258","article-title":"Gastrointestinal disorders in Down syndrome","volume":"179","author":"Bermudez","year":"2019","journal-title":"Am J Med Genet A"},{"key":"R20-20250530","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ridd.2016.06.018","article-title":"Overweight and obesity in children and adolescents with Down syndrome\u2014prevalence, determinants, consequences, and interventions: a literature review","volume":"57","author":"Bertapelli","year":"2016","journal-title":"Res Dev Disabil"},{"key":"R21-20250530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40263-015-0305-4","article-title":"The benzodiazepine-dementia disorders link: current state of knowledge","volume":"30","author":"Pariente","year":"2016","journal-title":"CNS Drugs"},{"key":"R22-20250530","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2018.3616","article-title":"Association of dementia with mortality among adults with Down syndrome older than 35 years","volume":"76","author":"Hithersay","year":"2019","journal-title":"JAMA Neurol"},{"key":"R23-20250530","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.psym.2017.10.009","article-title":"QT prolongation, torsades de pointes, and psychotropic medications: a 5-year update","volume":"59","author":"Beach","year":"2018","journal-title":"Psychosomatics"},{"key":"R24-20250530","first-page":"687","article-title":"QTc prolongation by psychotropic drugs and the risk of torsade de pointes","volume":"108","author":"Wenzel-Seifert","year":"2011","journal-title":"Dtsch Arztebl Int"},{"key":"R25-20250530","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"R26-20250530","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0304-3940(91)90787-T","article-title":"Fetal human brain exhibits a prenatal peak in the density of serotonin 5-HT1A receptors","volume":"127","author":"Bar-Peled","year":"1991","journal-title":"Neurosci Lett"},{"key":"R27-20250530","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0140-6736(65)90454-X","article-title":"Blood-serotonin deficiency in Down's syndrome","volume":"286","author":"Tu","year":"1965","journal-title":"Lancet"},{"key":"R28-20250530","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2788.1985.tb00320.x","article-title":"Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age","volume":"29","author":"Mann","year":"1985","journal-title":"J Intellect Disabil Res"},{"key":"R29-20250530","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0361-9230(01)00615-3","article-title":"Serotonin and brain development: role in human developmental diseases","volume":"56","author":"Whitaker-Azmitia","year":"2001","journal-title":"Brain Res Bull"},{"key":"R30-20250530","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0166-4328(02)00373-X","article-title":"Characterization of social behaviors and oxytocinergic neurons in the S-100\u03b2 overexpressing mouse model of Down Syndrome","volume":"141","author":"Borella","year":"2003","journal-title":"Behav Brain Res"},{"key":"R31-20250530","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/sj.npp.1300242","article-title":"Harm avoidance, anxiety, and response to novelty in the adolescent S-100\u03b2 transgenic mouse: role of serotonin and relevance to Down syndrome","volume":"28","author":"Bell","year":"2003","journal-title":"Neuropsychopharmacology"}],"container-title":["Journal of Developmental &amp; Behavioral Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DBP.0000000000000970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T18:03:03Z","timestamp":1748628183000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DBP.0000000000000970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/dbp.0000000000000970","relation":{},"ISSN":["0196-206X"],"issn-type":[{"value":"0196-206X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,7]]},"assertion":[{"value":"2020-08-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}